Patents by Inventor Ulrike Kuefner-Muehl

Ulrike Kuefner-Muehl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazotriazolopyrimidines with adenosine-antagonistic activity
    Patent number: 6492377
    Abstract: New imidazotriazolopyrimidine derivatives of the formula Preferred are those compounds wherein: R1 denotes methyl, which is optionally substituted by phenyloxy or pyrrole; or R1 denotes benzyl which is optionally substituted by hydroxy, methoxy, dimethylaminoethoxy or fluorine; or R1 denotes cyclopentyl, furan or phenylethyl; R2 or R3 denote ethyl, n-propyl, allyl or propargyl; R4 or R6 denote hydrogen; and, R5 denotes methyl, n-propyl, tert.butyl, cyclopentyl or norbornenyl. These are adenosine antagonists are are useful for, inter alia, the treatment of senile dementia of the Alzheimer's type.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: December 10, 2002
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Stefan Blech, Adrian Carter, Wolfram Gaida, Matthias Hoffmann, Ulrike Kuefner-Muehl, Christopher John Montague Meade, Gerald Pohl, Werner Kummer, Erich Lehr, Joachim Mierau, Thomas Weiser
  • Tricyclic nitrogen heterocycles as PDE IV inhibitors
    Patent number: 6417190
    Abstract: The invention relates to the use of tricyclic nitrogen heterocycles of general formula I as pharmaceutical compositions with an inhibitory effect on PDE IV, wherein the groups R1, R2 and R3 have the meanings given in the specification and claims.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: July 9, 2002
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Matthias Hoffmann, Birgit Jung, Ulrike Kuefner-Muehl, Christopher John Montague Meade
  • Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
    Patent number: 6187780
    Abstract: Asymmetrically substituted xanthine derivatives having adenosine A1 antagonistic activity. These are useful as pharmaceuticals. Exemplary are: (a) 3-(2-(2-acetyloxyethyl)sulphonylethyl)-8-(1-noradamantyl)-1-n-propyl-xanthine; (b) 3-(2-(hydroxyethyl)sulphonylethyl)-8-(1-noradamantyl)-1-n-propyl-xanthine; and, (c) 3-(2-(carbamoylethyl)-8-(1-noradanantyl)-1-n-propyl-xanthine.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: February 13, 2001
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Stefan Blech, Adrian Carter, Wolfram Gaida, Ursula Gath, Matthias Hoffmann, Ulrike Kuefner-Muehl, Erich Lehr, Joachim Mierau, Gerald Pohl, Thomas Weiser
  • New diazepines substituted in the 6-position, processes for their preparation and their use as pharmaceutical compositions
    Patent number: 5185442
    Abstract: The invention relates to new diazephines of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein, processes for preparing them and their use as pharmaceutical compositions useful for treating PAF-induced disease.
    Type: Grant
    Filed: January 15, 1992
    Date of Patent: February 9, 1993
    Assignee: Boehringer Ingelheim KG
    Inventors: Karl-Heinz Weber, Werner Stransky, Ulrike Kuefner-Muehl, Hubert Heuer, Franz Birke, Wolf-Dietrich Bechtel